Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Analgesics Stories

2013-01-29 16:23:26

In the news release, Underage Kids Get Hydrocodone Drugs Easily from Family & Friends, Advises New York Center for Living, issued 28-Jan-2013 by New York Center for Living over PR Newswire, we are advised by a representative of the company that as a result of editing errors the annexed press release contained certain factual inaccuracies in its original form. The release should have been as written below in its entirety. Underage Kids Get Hydrocodone Drugs Easily from Family &...

2013-01-29 12:27:08

NASHVILLE, Tenn., Jan. 29, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced it has entered into an exclusive agreement with Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the registration and commercialization of Caldolor® (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. Under the terms of the agreement, SOHO receives an exclusive license to Caldolor for the Indonesian market. SOHO will be...

2013-01-28 20:21:06

NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Sunday's front page of The New York Times New York edition headlined, "F.D.A. Likely to Add Limits on Painkillers," an advisory panel to the Food and Drug Administration voted 19 to 10 to recommend increased restrictions on hydrocodone products, the country's most widely used narcotic painkillers. Painkillers now take the lives of more Americans than heroin and cocaine combined, and since 2008, drug-induced deaths have outstripped those from...

2013-01-28 12:26:21

CHARLESTON, S.C., Jan. 28, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today that patient enrollment has begun for the company's pivotal Phase 3 clinical trial for its first product, CL-108, for the treatment of moderate to severe pain. "The...

2013-01-23 08:28:21

SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV(®) (acetaminophen) injection for the three-months ended December 31, 2012, of approximately $17.1 million. "We ended 2012 on a high note, with...

2013-01-07 12:28:01

NORTH LIBERTY, Iowa, Jan. 7, 2013 /PRNewswire/ -- KemPharm, Inc, a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Adopted Name (USAN) Council approved the use of the nonproprietary name, "benzhydrocodone," for its lead pain candidate, KP201. KP201 is in development for the treatment of acute moderate to moderately severe pain with a new drug application (NDA) expected to be...

2013-01-02 16:22:38

DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT). Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, will present an overview of the company and provide a business and financial update. The webcast can be...

2012-12-26 16:20:51

NEWARK, Calif., Dec. 26, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that its lawsuits against two filers of Abbreviated New Drug Applications (ANDAs) for Gralise(®) (gabapentin) have been dismissed. Watson Laboratories has withdrawn its Gralise ANDA. Par Pharmaceutical has amended its Gralise ANDA and is no longer seeking approval of the ANDA prior to the expiration of Depomed's patents listed for Gralise in the FDA publication commonly known as the Orange Book....

2012-12-20 08:26:34

PITTSBURGH, Dec. 20, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business is conducting a voluntary nationwide recall to the retail level of three lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg (Lots 3037841, 3040859 and 3042573). The three lots were manufactured by Qualitest Pharmaceuticals, and Mylan Institutional repackaged and distributed the product in unit dose (CD100) under the UDL Laboratories, Inc. (n/k/a...

2012-12-12 08:27:23

SAN DIEGO, Calif., Dec. 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that it has entered into an agreement to terminate its exclusive option to acquire privately-held Incline Therapeutics, Inc., or Incline. Under the waiver, consent and option termination agreement signed by Cadence and...